Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 34110, Doha, Qatar.
Curr Diab Rep. 2019 Aug 10;19(9):83. doi: 10.1007/s11892-019-1194-6.
To discuss the current understanding of "β cell identity" and factors underlying altered identity of pancreatic β cells in diabetes, especially in humans.
Altered identity of β cells due to dedifferentiation and/or transdifferentiation has been proposed as a mechanism of loss of β cells in diabetes. In dedifferentiation, β cells do not undergo apoptosis; rather, they lose their identity and function. Dedifferentiation is well characterized by the decrease in expression of key β cell markers such as genes encoding major transcription factors, e.g., MafA, NeuroD1, Nkx6.1, and Foxo1, and an increase in atypical or "disallowed" genes for β cells such as lactate dehydrogenase, monocarboxylate transporter MCT1, or progenitor cell genes (Neurog3, Pax4, or Sox9). Moreover, altered identity of mature β cells in diabetes also involves transdifferentiation of β cells into other islet hormone producing cells. For example, overexpression of α cell specific transcription factor Arx or ablation of Pdx1 resulted in an increase of α cell numbers and a decrease in β cell numbers in rodents. The frequency of α-β double-positive cells was also prominent in human subjects with T2D. These altered identities of β cells likely serve as a compensatory response to enhance function/expand cell numbers and may also camouflage/protect cells from ongoing stress. However, it is equally likely that this may be a reflection of new cell formation as a frank regenerative response to ongoing tissue injury. Physiologically, all these responses are complementary. In diabetes, (1) endocrine identity recapitulates the less mature/less-differentiated fetal/neonatal cell type, possibly representing an adaptive mechanism; (2) residual β cells may be altered in their subtype proportions or other molecular features; (3) in humans, "altered identity" is a preferable term to dedifferentiation as their cellular fate (differentiated cells losing identity or progenitors becoming more differentiated) is unclear as yet.
讨论目前对“β 细胞身份”的理解,以及糖尿病中(尤其是在人类中)胰腺β 细胞身份改变的潜在因素。
由于去分化和/或转分化导致的β 细胞身份改变被认为是糖尿病中β 细胞丢失的一种机制。在去分化中,β 细胞不会发生凋亡,而是失去其身份和功能。β 细胞的去分化特征是关键β 细胞标志物的表达减少,例如编码主要转录因子的基因,如 MafA、NeuroD1、Nkx6.1 和 Foxo1,以及β 细胞中不典型或“不允许”的基因(如乳酸脱氢酶、单羧酸转运蛋白 MCT1 或祖细胞基因,如 Neurog3、Pax4 或 Sox9)的增加。此外,糖尿病中成熟β 细胞的身份改变还涉及β 细胞向其他胰岛激素产生细胞的转分化。例如,在啮齿动物中过表达α 细胞特异性转录因子 Arx 或敲除 Pdx1 会导致α 细胞数量增加和β 细胞数量减少。在 T2D 患者中也明显存在α-β 双阳性细胞的频率。这些β 细胞的改变身份可能是增强功能/扩大细胞数量的代偿性反应,也可能掩盖/保护细胞免受持续的应激。然而,同样有可能的是,这可能反映了新细胞形成作为对持续组织损伤的再生反应。从生理上讲,所有这些反应都是互补的。在糖尿病中,(1)内分泌身份重现了不成熟/分化程度较低的胎儿/新生儿细胞类型,这可能代表一种适应性机制;(2)残留的β 细胞可能在其亚型比例或其他分子特征上发生改变;(3)在人类中,“改变的身份”是比去分化更合适的术语,因为其细胞命运(分化细胞失去身份或祖细胞变得更分化)尚不清楚。